About the project
CRyPTIC’s aim is to help improve control of tuberculosis and facilitate WHO’s End TB Strategy by better, faster and more targeted treatment of drug-resistant tuberculosis via genetic resistance prediction, paving the way towards universal drug susceptibility testing (DST).
Our ultimate goal is to achieve sufficiently accurate genetic prediction of resistance to most anti-tuberculosis drugs, so that whole genome sequencing can replace culture-based DST for TB. This will enable rapid-turnaround near-to-patient assays to revolutionise MDR-TB identification and management. This project is funded by MRC Newton Fund, Wellcome Trust, and Bill & Melinda Gates Foundation.